News :: Matinas BioPharma Holdings, Inc. (MTNB)

Matinas in the news.

Feb 13, 2025 • 5:00 PM EST

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Feb 7, 2025 • 7:30 AM EST

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

Jan 10, 2025 • 5:15 PM EST

Matinas BioPharma Receives NYSE Noncompliance Notice

View all news

MAT2203: Encochleated formulation of amphotericin B

A Novel Encochleated Atovaquone Formulation is Active in a Murine Model of Pneumocystis Pneumonia

View

Efficacy of Oral Cochleate-Amphotericin B for the Prevention of Invasive Candidiasis in Neutropenic Mice

View

Oral Dosing of Encochleated Amphotericin B (CAmB): RapOral Dosing of Encochleated Amphotericin B (CAmB): Rapid Drug Targeting to Infected Tissues in Mice with Invasive Candidiasis; A-054: Mannino/Perlin: ICAAC 2015

View

Oral Administration of Amphotericin B (Oral Administration of Amphotericin B (CAmB) in Humans: a Phase I Study of Tolerability and Pharmacokinetics - Data showing results from Phase I clinical trial; Phase 1 SAD: Imedex’ “Focus on Fungal Infections” 2009**

View

Oral Administration of Amphotericin B: Toxicokinetic Studies in Animal Models - Data showing reduced toxicity of oral encochleated amphotericin B; 28-day Rat/Dog Tox: “Focus on Fungal Infections” 2009**

View

Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis; Antimicrob Agents Chemother. 2002 Aug; 46(8): 2704–2707

View

Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic Candidiasis; Antimicrob Agents Chemother. 2000 Sep; 44(9): 2356–2360

View

Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model; Antimicrob Agents Chemother. 2000 Jun; 44(6): 1463–1469

View

Efficacy in Mouse model of Cryptococcal Meningoencephalitis; Crypto slides: AIDS- Associated Mycoses scientific meeting, Capetown, July 2016

View

Efficacy of Oral Encochleated Amphotericin B (CAMB) in a Mouse Model of Cryptococcal Meningoencephalitis; Poster Presentation 189 ASM Microbe 2017

View

Oral Encochleated Amphotericin B (CAMB) in the Treatment of Chronic Azole Resistant Mucocutaneous Candidiasis; Poster Presentation 240 ASM Microbe 2017

View

Other Cochleate Technology Data

IDWeek 2016 Poster - Formulation of Orally and Intranasally Administered Influenza Vaccine in Cochleate Lipid-Crystal Nano-Particles Significantly Enhances Immune Response in Murine Models of Influenza; IDweek 2016 flu vaccine poster

View

Biotech 2012 Innovation Corridor - Our technology was featured at the Biotech 2012 Innovation Corridor for the demonstrated ability to orally deliver antimicrobial drugs. Our poster was selected as one of the winners by a panel of judges; Biotech 2012 Corridor: technology poster

View

Efficacy of a Nanocochleate-Encapsulated 3,5-Diaryl- s-Triazole Derivative in a Murine Model of Graft-Versus- Host Disease; Transplantation. 2008 Jul 15;86(1):171-5. doi: 10.1097/TP.0b013e31817ba761

View

Pharmacokinetics and Efficacy of Encochleated Atovaquone (CATQ) in Murine Model of Pneumocystis; IDweek 2015 Poster presentation CATQ by NIH

View

10 mg /Kg lung (outlier) Lipid-Crystal Nano-Particles: Formulation and Delivery of Oligonucleotides; CHI April 2016 Boston conference Poster on “oligonucleotides”

View

Formulation of Ibuprofen in Lipid-Crystal Nano-Particles Enhances Efficacy and Reduces Gastric Mucosal Erosions in a Rat Carrageenan-induced Paw Inflammation Model; EULAR June 2016 abstract on encochleated Ibuprofen

View

PAST EVENTS

Aug 14 2024

Second Quarter 2024 Results Conference Call and Webcast

Webcast Related Materials

Jun 18 2024

Fireside Chat with Dr. David Perlin

Webcast Related Materials

May 10 2024

ASGCT 27th Annual Meeting

Related Materials

View All Events